GlassScriptPhysician profile
Amanda Mulig
NPI 1437692605
$1,672.27
in general payments reported to CMS, 2019-2025
12 companies · $14.72 in 2025
The $14.72 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $555 · 2023: $329 · 2024: $144 · 2025: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $452.79 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.07 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $290.79 | 2021-2024 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $210.49 | 2022-2024 | |
| Abbvie INC. | $163.72 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $30.63 | 2024-2025 | Airsupra |
| Zealand Pharma US, INC. | $24.01 | 2021 | |
| Pfizer INC. | $16.14 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.92 | 2024 | Voquezna |
| Abbott Laboratories | $12.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mulig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.